CGTK Corgentech Inc. (MM)

Additional Data in Morton's Neuroma Also Presented; Abstracts #5659 and #5663 at American Pain Society Meeting SAN ANTONIO and SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- Corgentech Inc. (NASDAQ:CGTK) today announced the presentation of promising primary and secondary data from two Phase 2 clinical trials of 4975, Corgentech's novel, long-acting, non-opioid drug candidate, in patients with elbow tendonitis (acute lateral epicondylitis) and Morton's neuroma (intermetatarsal neuroma), a painful foot condition, at the 25th Annual Scientific Meeting of the American Pain Society. New, secondary data from the tendonitis trial demonstrated that patients treated with a single, local injection of 4975 exhibited sustained, significant reductions at all pain endpoints and a significant improvement in function, compared to the placebo group at the 4-week observation period. The meeting is being held in San Antonio, TX. "Tendonitis is a debilitating condition with very painful symptoms that can last for months and current treatment options have inconsistent efficacy. This study shows that treatment with 4975 not only effectively manages pain, but improves function by more than 50 percent at four weeks," stated Daniel J. Gennevois, M.D., vice president of Medical Affairs at Corgentech. 4975 Reduces Pain of Acute Lateral Epicondylitis: Preliminary Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 2, Multicenter Clinical Trial In this Phase 2 trial, patients with acute elbow tendonitis received a single, local injection of 100 micrograms of 4975 or placebo at the site of pain, preceded by an injection of a local anesthetic. At 4 weeks, 64 percent (14/22) of patients treated with 4975 experienced decreased pain during resisted wrist movement, compared to 30 percent (7/23) of patients treated with placebo (p = 0.026). Treatment with 4975 also resulted in an approximately 60 percent improvement from baseline in grip strength at 4 weeks, compared to an approximate 14 percent improvement in the placebo group (p = 0.009). Importantly, treatment with 4975 produced a significant improvement on patients' global impression of change in pain at all post treatment time points compared to placebo. At week 4, 64 percent (14/22) of the 4975 patients categorized themselves as "very much improved" or "improved" since elbow injection versus 22 percent (5/23) of patients in the placebo group. With the exception of pain on injection (which was managed with icepacks), 4975 was well tolerated, causing no other treatment-related adverse events, no decreases in sensory function, and no significant local reactions of the skin. 4975 Reduces Pain of Intermetatarsal Neuroma: Preliminary Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 2, Multicenter Clinical Trial In the Phase 2 Morton's neuroma trial, patients who had failed conservative treatments including analgesics and steroid injections received a single local injection of 100 micrograms of 4975 or placebo at the site of pain, preceded by an injection of a local anesthetic. Patients treated with 4975 experienced greater pain relief compared to placebo as measured by change from baseline in average weekly foot pain, sum of average foot pain intensity, change from baseline in pain-related interference items of the Brief Pain Inventory, and patients' use of supplemental analgesic medication. Importantly, significantly superior pain reduction occurred early, at 1 week after start of treatment, and was sustained at the 4-week observation period (p